Evidence map›Paper›PMID 40956998›Full record

ArticleJCO precision oncology2025

Fibroblast Growth Factor Receptor 3 Alteration Status and Outcomes on Immune Checkpoint Inhibitors in Patients With Metastatic Urothelial Carcinoma.

Shilpa Gupta, Jessica K Lee, Jerry Mitchell, Richard S P Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Biomarkers and testing in pathology.Current opinion in urology · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shilpa GuptaCleveland Clinic Taussig Cancer Institute, Cleveland, OH.ORCID 0000-0002-8775-503X
Jessica K LeeFoundation Medicine, Inc, Boston, MA.ORCID 0000-0002-4333-5092
Jerry MitchellFoundation Medicine, Inc, Boston, MA.ORCID 0009-0001-8029-8788
Richard S P HuangFoundation Medicine, Inc, Boston, MA.ORCID 0000-0001-8395-5168

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe use of immune checkpoint inhibitors (ICPIs) has expanded in the treatment of metastatic urothelial carcinoma (mUC), but response rates are variable, highlighting the need for predictive biomarkers. Tumor mutational burden (TMB) has been shown to predict response to ICPI, but Fibroblast Growth Factor Receptor 3 (

methodsA total of 1,416 patients with mUC who received hybrid-capture next-generation sequencing (NGS)-based genomic profiling were evaluated for their response to ICPI and chemotherapy based on the presence of

resultsAmong 819 patients with mUC who received ICPI, there were no significant differences in rwOS or rwPFS between

conclusionWhile

Indexed as

Carcinoma, Transitional CellImmune Checkpoint InhibitorsReceptor, Fibroblast Growth Factor, Type 3Urinary Bladder NeoplasmsUrologic NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationNeoplasm MetastasisTreatment OutcomeFGFR3 protein, humanImmune Checkpoint InhibitorsReceptor, Fibroblast Growth Factor, Type 3

Identifiers

PMID40956998
PMCPMC12442780

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.